Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control studyArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] 95% CI adjusted hazard ratio Antiviral antiviral. ARMS clinical clinical condition Clinical improvement complications control arm COVID-19 COVID-19 patient Day defined early treatment Effect Efficacy enrolled enrolment faster Favipiravir female FPV investigated likelihood median median time mild case mild pneumonia multicentre Patient PCR-confirmed Pneumonia primary endpoint randomized control study RdRP RdRp inhibitor registry risk of COVID-19 SARS-CoV-2-infected patient score significantly higher supportive care sustained symptomatic Thailand Treatment viral clearance Viral detection [DOI] 10.1080/22221751.2022.2117092 PMC 바로가기
Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infectionsArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition Anti-RBD IgG antibody Breakthrough infection Cell cellular immunity cellular response circulating Delta Diagnosis Dynamics exhibited faster greater HCW HCWs healthcare worker humoral IFN-γ Immunity Infection infectiousness investigated isolates median neutralization capacity neutralizing antibody titre normalized omicron pandemic positive pre-existing immunity proportion reported RT-qPCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 isolates SARS-CoV-2 peptides SARS-CoV-2 variants symptom onset Vaccine vaccine-immunity variant viral clearance viral culture Viral load viral loads viral shedding Viral shedding. [DOI] 10.1080/22221751.2022.2122578 PMC 바로가기
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in miceArticle Published on 2022-11-022022-11-15 Journal: PLoS ONE [Category] SARS, 변종, 진단, [키워드] Activation Arm cellular COVID-19 disease demonstrated development disease Efficacy hamster humoral IgA immune Immunity immunization induce intramuscular intramuscularly intranasal intranasally Lower respiratory tract lung Lung pathology medical need memory B cell mice mucosal mucosal immune pandemic promote protective immunity public health rapid progress response resulting robust S-2P Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine Seroconversion Spike protein systemic immune response the SARS-CoV-2 Transmission unique upper respiratory tract Vaccine vaccine candidate variants viral clearance weight loss while [DOI] 10.1371/journal.pone.0272594 PMC 바로가기
Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 VaccineArticle Published on 2022-10-252022-11-15 Journal: ACS Nano [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, [키워드] ACM acute respiratory syndrome adverse effect airway antibodies antibody antigen presenting cells artificial Beta Beta spike C57BL/6 cell membrane clinical symptom clinical trial component conditions coronavirus coronavirus disease COVID-19 CpG cross-neutralizing current delivery of cargo dendritic cells dose doses evaluate evaluated Formulation generate Generation Good hamster hamsters immune responses immunization immunogenic induce Infection initiated interval intranasal mice neutralize neutralizing antibody neutralizing responses New omicron Phase 1 polymersome Practice PROTECT reduction repeated Safety SARS-CoV-2 second serum IgG spike Spike protein Spike-based vaccine Support Toxicity upper respiratory tract Vaccine vaccine. variants viral clearance Viral load virus weight loss wild type [DOI] 10.1021/acsnano.2c06350 PMC 바로가기
Clinical predictors and RT-PCR profile of prolonged viral shedding in patients with SARS-CoV-2 Omicron variant in Shanghai: A retrospective observational studyArticle Published on 2022-10-242022-11-16 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome Admission Analysis analysis clearance clinical Comorbidity Coronary heart disease coronavirus Ct values cycle threshold determinant diabetes equation evaluate Frame Generalized group hospitalized patient hypertension Infection male material median age multivariable analysis N gene nasopharyngeal nucleocapsid protein omicron ORF ORF 1ab gene Patient patients with SARS-CoV-2 positive predictor predictors prolonged SARS-CoV-2 RNA shedding. prolonged viral shedding proportion receiving remained retrospective Retrospective study RT-PCR SARS-CoV-2 SARS-CoV-2 Omicron variant SARS-CoV-2 RNA significantly single-center tested the timing vaccination Vaccinations Vaccine variant viral clearance viral RNA clearance Viral RNA shedding [DOI] 10.3389/fpubh.2022.1015811 PMC 바로가기
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a PartArticle Published on 2022-10-182022-11-15 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome All adverse event Asymptomatic baseline clinical coronavirus coronavirus disease COVID-19 Culture demonstrated double-blind Efficacy and safety ensitrelvir fumaric acid greater group groups intention-to-treat population Japan Japanese log median time Mild Mild-to-moderate moderate multicenter novel oral Part Patient phase phase 2/3 Placebo positive Primary outcome proof-of-concept study protease Protease inhibitor Randomized receive reduced registry Result S-217622 SARS-CoV-2 SARS-CoV-2 3C-like protease inhibitor SARS-CoV-2 clearance SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2 viral the SARS-CoV-2 tissue Treatment viral clearance Viral RNA viral titer viral titer. [DOI] 10.1128/aac.00697-22 PMC 바로가기
Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysisArticle Published on 2022-09-292022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome addition Antibody Response Antigen BAL Bronchoalveolar lavage clearance coronavirus coronavirus disease COVID-19 cross-sectional analysis domain fatal COVID-19 function IgA IgG IL-1β immune complex Infection Inflammatory Inflammatory cytokine lung mucosal mucosal immunity neutralization Neutralizing activity Neutralizing titer nucleocapsid protein outcome Patient persistent Protective RBD RBD variants reduced replicate SARS-CoV-2 SARS-CoV-2-specific antibody severe COVID-19 patients Severe infection severe infection. Survivors tested viral clearance virus virus virus elimination with COVID-19 Wuhan [DOI] 10.3389/fimmu.2022.842468 PMC 바로가기
SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recoveryArticle Published on 2022-09-282022-11-15 Journal: Science Translational Medicine [Category] SARS, 진단, 치료기술, [키워드] acute respiratory syndrome affected animal model change coronavirus correlated COVID COVID-19 demonstrated detectable exceeded hamster highlight host response Human IAV individual Infection Infectious virus influenza A virus Injury interferon response kidney lack lung mechanism molecular mechanism olfactory Olfactory epithelium PASC pathology Perturbation Proinflammatory cytokine response Result SARS-CoV-2 SARS-COV-2 infection sustained T cell activation tissue transcriptional change unique viral clearance [DOI] 10.1126/scitranslmed.abq3059 PMC 바로가기
A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)Article Published on 2022-09-272022-11-15 Journal: BMC Medicine [Category] SARS, 진단, [키워드] 95% confidence interval Administered age airway analysis asymptomatic patients Bayesian camostat camostat mesilate cardiovascular diseases cells Chronic kidney disease chronic respiratory disease clinical conducted consecutive negative test conversion COVID-19 COVID-19 symptom Diabetes Mellitus dose double-blind Drug screening effective Efficacy and safety eight enrolled evaluate Factor first test hospital human airway epithelial hypertension indicated Japan median time Mild moderate multicenter no significant difference obesity parallel-group Patient patients patients with COVID-19 Placebo placebo-controlled study Positive test Prevent primary efficacy endpoint Randomized Randomized controlled trial receive reduce registry SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2. the placebo group the primary endpoint Treatment two groups underlying disease viral clearance viral loads was performed were blinded were excluded without symptoms [DOI] 10.1186/s12916-022-02518-7 PMC 바로가기
Low baseline IFN-γ response could predict hospitalization in COVID-19 patientsArticle Published on 2022-09-262022-11-15 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, [키워드] addition administration age Analysis baseline Biomarker clinician Contact COVID-19 patient deaths Deleterious early stage Efficacy form functional functional immunoassay help Hospitalization Hospitalized IFN-γ IL-6 immunoassay individual Infection Inflammatory response inverse correlation investigated multivariable analysis Personalized medicine plasma predict Predictive predictive biomarker reduce mortality risk SARS-CoV-2 SARS-COV-2 infection Spearman Spread subject Treatment vaccination viral clearance viral infection Viral infection. [DOI] 10.3389/fimmu.2022.953502 PMC 바로가기